Single-dose Vaginal Dinoprostone and Hysterectomy

NCT ID: NCT04080323

Last Updated: 2020-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-25

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we will assess the efficacy of dinoprostone in minimizing blood loss during hysterectomy when used as a single preoperative dose via the vaginal route. The reduction of blood flow may be due to the combined effect of myometrial contraction and vasoconstrictive effect

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hysterectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dinoprostone 3 mg

60 minutes before the surgery 3 mg of dinoprostone inserted vaginally

Group Type EXPERIMENTAL

Dinoprostone 3 mg

Intervention Type DRUG

1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery

placebo

60 minutes before the surgery 1 tablet of placebo inserted vaginally

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

1 vaginal tablet of placebo 60 minutes before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dinoprostone 3 mg

1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery

Intervention Type DRUG

placebo

1 vaginal tablet of placebo 60 minutes before surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients presenting for hysterectomy for any benign indication including uterine fibroids.

* Age ≥ 18 years
* Pre-operative hemoglobin \>8 g/dl
* Willing to have dinoprostone or a placebo prior to hysterectomy
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria

* • Patients with known or suspected endometrial/ovarian/cervical cancer.

* Patients undergoing hysterectomy for endometrial hyperplasia or cervical dysplasia.
* Patients currently undergoing treatment for any type of cancer.
* Patients with known bleeding/clotting disorders or a history of thromboembolism (including deep venous thrombosis or pulmonary embolism)
* History of allergic reactions to dinoprostone.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Samy aly ashour

assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AHMED SAMY

Role: STUDY_DIRECTOR

Cairo University

ayman taher, MD

Role: PRINCIPAL_INVESTIGATOR

Cairo University

ahmed S Ali

Role: PRINCIPAL_INVESTIGATOR

faculty of medicine al-azhar university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ahmed Samy

Giza, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

dinoprostone hysterectomy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Misoprostol+Oxytocin vs. Carbetocin in CS
NCT02786992 COMPLETED PHASE2/PHASE3